<DOC>
	<DOCNO>NCT01876849</DOCNO>
	<brief_summary>The aim study ass long-term safety exenatide patient type 2 diabetes treat exenatide Study H8O-MC-GWAA ( 6-month study ) Study H8O-MC-GWAD ( 12-month study ) . Study H8O-MC-GWAN serf open-ended extension Studies H8O-MC-GWAA H8O-MC-GWAD .</brief_summary>
	<brief_title>An Open-Label Study Examining Long-Term Safety Exenatide Given Twice Daily Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patients receive exenatide therapy Study H8OMCGWAA Study H8OMCGWAD complete respective study . Patients exclude discontinue early Study H8OMCGWAA Study H8OMCGWAD . Patients receive treatment within last 30 day drug , include exenatide , receive regulatory approval indication time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>